AIR ? an open-label, 36-week, clinical trial of buloxibutid ? investigating the disease modifying potential of a novel angiotensin II type 2 receptor agonist in IPF - Vienna 2024

Novel management strategies in pulmonary fibrosis

Chair(s): Laura Fabbri, Wim A. Wuyts

Session type: Oral presentation

AIR ? an open-label, 36-week, clinical trial of buloxibutid ? investigating the disease modifying potential of a novel angiotensin II type 2 receptor agonist in IPF

Cecilia Ganslandt

EVENTS HOME

Previous presentation

Next presentation

Session content

Late Breaking Abstract - Dietetic intervention in malnourished patients with interstitial lung disease (ILD): a pilot trial

Rasleen Kahai

Replay

Poster

Abstract

Slides

AIR an open-label, 36-week, clinical trial of buloxibutid investigating the disease modifying potential of a novel angiotensin II type 2 receptor agonist in IPF

Cecilia Ganslandt

Replay

Poster

Abstract

Slides

Effects of lysophosphatidic acid receptor 1 (LPA1) antagonism on biomarkers in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF): data from a randomized phase 2 trial with BMS-986278

Toby M Maher

Replay

Poster

Abstract

Slides

Safety and tolerability of bexotegrast in Phase 2 trials of idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC)

Gregory Cosgrove

Replay

Poster

Abstract

Slides

Validation of electronic nose technology as diagnostic tool for different fibrotic interstitial lung diseases

Catharina C. Moor

Replay

Poster

Abstract

Slides

Development and Evaluation of a Comprehensive Machine Learning Tool Differentiating Idiopathic Pulmonary Fibrosis from Other Interstitial Lung Diseases in the Japanese nationwide registry (PROMISE study).

Taiki Furukawa

Replay

Poster

Abstract

Slides

Disease trajectory of newly diagnosed patients with pulmonary fibrosis using online home spirometry in the international multicenter I-FILE study

Gizal Nakshbandi

Replay

Abstract

Slides

Health outcomes in IPF and PPF: European survey on healthcare professionals views and practices

Vivien Somogyi

Replay

Poster

Abstract

Slides

Late Breaking Abstract - A deep learning algorithm for predicting progression in fibrosing interstitial lung disease

Caitlin Fermoyle

Replay

Abstract

Slides

Effect of telomere length and TERT/TERC rare variants on survival in Japanese patients with idiopathic interstitial pneumonias?Genetic predisposition study from the Japanese Idiopathic Interstitial Pneumonias (JIPS) Registry (NEJ036A)

Shu Hisata

Replay

Abstract

Slides

Discussion and Q&A

Replay

CDN Connection Issue

The ERS Congress 2024, Vienna

#{title}